DBT Bureau
Pune, 3 Feb 2026
Despite a sequential dip in revenue during Q3 FY26, CORONA Remedies delivered strong margin expansion and profit growth, with PAT rising 6.2% QoQ and EBITDA margin improving sharply by 260 bps, highlighting improved operational efficiency and cost discipline.
Q1 vs Q2 vs Q3 FY26 – Financial Performance & QoQ Growth
| Particulars | Q1 FY26 | Q2 FY26 | Q3 FY26 | QoQ Change (Q3 vs Q2) |
|---|---|---|---|---|
| Revenue from Operations (₹ Cr.) | 346.50 | 361.13 | 342.42 | -5.18% |
| EBITDA (₹ Cr.) | — | — | 83.16 | — |
| EBITDA Margin (%) | 20.72% | 21.70% | 24.30% | +260 bps |
| Profit After Tax (₹ Cr.) | 46.10 | 52.32 | 55.56 | +6.19% |
| PAT Margin (%) | 13.33% | 14.50% | 16.20% | +170 bps |
Previous result comparisons :
